ストックスクリーナーアプリを入手
2.97
0.00%
0.00
アフターアワーズ：
2.99
0.02
+0.67%
前日終値:
$2.97
開ける：
$3.01
24時間の取引高:
2.33M
Relative Volume:
0.93
時価総額：
$536.43M
収益：
$4.63M
当期純損益:
$-201.14M
株価収益率:
-2.1614
EPS:
-1.3741
ネットキャッシュフロー:
$-167.10M
1週間 パフォーマンス:
+10.00%
1か月 パフォーマンス:
-19.73%
6か月 パフォーマンス:
-19.95%
1年 パフォーマンス:
+130.23%
1日の値動き範囲:
$2.89
$3.05
1週間の範囲:
$2.70
$3.0999
52週間の値動き範囲:
$1.18
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Compare PRME vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
2.97 | 536.43M | 4.63M | -201.14M | -167.10M | -1.3741 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 開始されました | Oppenheimer | Outperform |
| 2025-05-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-05-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2024-04-22 | 開始されました | Chardan Capital Markets | Buy |
| 2024-04-08 | 開始されました | TD Cowen | Buy |
| 2024-04-03 | 開始されました | Wedbush | Outperform |
| 2024-01-16 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-10-09 | 開始されました | BMO Capital Markets | Outperform |
| 2023-07-31 | 開始されました | Guggenheim | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2022-11-14 | 開始されました | Goldman | Neutral |
| 2022-11-14 | 開始されました | JP Morgan | Overweight |
| 2022-11-14 | 開始されました | Jefferies | Buy |
| 2022-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prime Medicine Inc (PRME) 最新ニュース
PRME Q1 2026 Earnings: EPS Worse Than Expected as Pre-Revenue Biotech Advances PipelinePro Level Trade Signals - Newser
PRME Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Consistency Score - Newser
Prime Medicine (PRME) Q1 2026 Disappoints — EPS $-0.28 Below $-0.26 ViewsEarnings Turnaround - Newser
Prime Medicine slips after Q4 updates - MSN
Prime Medicine (PRME) Reports Q1 EPS - Yahoo Finance
10 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Oppenheimer Maintains Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $11 - Moomoo
TradingKey - TradingKey
Prime Medicine, Inc. (PRME) reports Q1 loss, misses revenue estimates - MSN
Number of shareholders of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
PRME Prime Medicine revenue jumps 55% YoY in Q1; shares rally 3% on growth momentum.Management Guidance - newser.com
JonesTrading Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $5 - Moomoo
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating - Moomoo
The opportunity most miss about Prime Medicine (PRME) (-8.65%) 2026-05-08Analyst Recommended Stocks - Newser
Prime Medicine Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Prime Medicine (NASDAQ:PRME) Q1 Results Show Revenue Miss and Narrower Loss as Key Pipeline Milestones Loom - ChartMill
PRIME MEDICINE ($PRME) Releases Q1 2026 Earnings - Quiver Quantitative
[10-Q] Prime Medicine, Inc. Quarterly Earnings Report - Stock Titan
Prime Medicine Q1 net loss narrows as R&D expenses fall - TradingView
Prime Medicine (Nasdaq: PRME) Q1 2026 results, cash runway into 2027 and pipeline update - Stock Titan
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Prime Medicine targets 2 liver disease filings in 2026, data due 2027 - Stock Titan
Top Prime Medicine (PRME) Competitors 2026 - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen - MarketBeat
PRME SEC FilingsPrime Medicine 10-K, 10-Q, 8-K Forms - Stock Titan
PRME - Finviz
PRME Stock Price, Quote & Chart | PRIME MEDICINE INC (NASDAQ:PRME) - ChartMill
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - MSN
Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen - MarketBeat
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
PRME Price Today: Prime Medicine, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Prime Medicine, Inc. ($PRME) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Prime Medicine, Inc. SEC Filing - Stock Titan
Prime Medicine (NASDAQ: PRME) details 2026 meeting, board elections and pay - Stock Titan
PRME (Prime Medicine Inc.) posts 55 percent year over year Q4 2025 revenue growth, shares rise modestly. - Xã Thanh Hà
Prime Medicine slides after pricing $125.4M stock offering - MSN
HC Wainwright & Co. Downgrades Prime Medicine (PRME) - MSN
Prime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial Officer - Yahoo Finance
Bristol Myers Squibb (BMY) – Gene Editing Partner Prime Medicine (PRME) Announces Strategic CFO Hire, Bullish Analyst InitiationRisk Report - Cổng thông tin điện tử tỉnh Lào Cai
Prime Medicine (PRME) Financials 2026Income Statement and Balance Sheet - MarketBeat
Wall Street Zen Upgrades Prime Medicine (NASDAQ:PRME) to Sell - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 384,418 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (PRME) awards CFO 800,000 stock options at $3.67 - Stock Titan
Prime Medicine (PRME) CFO Makhni Svetlana Ni submits initial Form 3 - Stock Titan
Prime Medicine Inc (PRME) 財務データ
収益
当期純利益
現金流量
EPS
Prime Medicine Inc (PRME) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):